Welcome   Guest   [Login | Register] Sign in with Facebook Sign in with Google Sign in with Yahoo!
logoRelationalStocks.com
STOCK TICKER:
Metabasis Therapeutics Inc.   (ticker: MBRX)
Quote:Moleculin Biotech Inc.(MBRX) MBRX Quotes on: Yahoo | Google
1.84
0.03 (1.604%)
5 day's Perf: 8.91%
1 Month Perf: 19.29%
3 Month Perf: 44.91%
YTD Perf: 19.29%
1 Year Perf: N/A%
Stock chart
Useful Quick Links for MBRX
Financial Key Date: Yahoo
Option Prices: MarketWatch
Technical Opinion: Barchar.com
Technical Charts: StockCharts.com
Analyst & Estimates: Reuters
Ratings: TheStreet.com
SEC Filings: EDGAR Online
Message Boards: Yahoo | TheLion
Insiders' Indicator :          Hold          (Click Here For Details)
INSIDERS' Score: 45
0 100 45
BuySell
Latest 1 month: 0 0
Latest 6 Months: 0 0
52 Weeks: 0 200,000
Gurus' Indicator :          Hold          (Click Here For Details)
GURUS' Score: 50
0 100 50
Current Holdings: 0
Previous Holdings: 0
Change: 0
Institutions' Indicator :          Hold          (Click Here For Details)
INSTITUTIONS' Score: 50
0 100 50
Current Holdings: 0
Previous Holdings: 0
Change: 0
News And Links For The Group (Contribute a link)
[MBRX]   A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals  (Seeking Alpha)   16-Jun-18 09:00
[MBRX]   Developing Cancer Treatment Trials Positive Indication for Biotech Market  (PR Newswire)   12-Jun-18 08:30
[MBRX]   Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference  (Marketwire)   26-Apr-18 08:30
[MBRX]   Moleculin Enters Agreement with BSP Pharmaceuticals for its Leukemia Drug Candidate  (Marketwire)   24-Apr-18 08:30
[MBRX]   Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax  (PR Newswire)   18-Apr-18 06:35
[MBRX]   Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial  (Marketwire)   4-Apr-18 08:30
[MBRX]   Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017  (Marketwire)   28-Mar-18 08:30
[MBRX]   Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials  (Marketwire)   27-Mar-18 08:30
[MBRX]   Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery  (Marketwire)   20-Mar-18 08:30
[MBRX]   Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018  (Marketwire)   6-Mar-18 08:30
[MBRX]   Reminder: Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018  (Marketwire)   28-Feb-18 10:05
[MBRX]   Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018  (Marketwire)   22-Feb-18 08:30
[MBRX]   Moleculin Announces Pricing of $9 Million Registered Direct Offering  (Marketwire)   16-Feb-18 08:28
[MBRX]   Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment  (Marketwire)   15-Feb-18 08:30
[MBRX]   Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer  (Marketwire)   13-Feb-18 08:30
[MBRX]   Moleculin Announces Activity with Pancreatic Cancer Drug  (Marketwire)   7-Feb-18 08:30
[MBRX]   Leading Leukemia Experts Join Moleculin's Science Advisory Board  (Marketwire)   17-Jan-18 08:30
[MBRX]   Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor  (Marketwire)   10-Jan-18 08:30
[MBRX]   Moleculin Announces Polish Approval for Leukemia Clinical Trial  (Marketwire)   21-Dec-17 08:30
[MBRX]   Moleculin's WP1066 Drug receives $2 million Private Grant  (Marketwire)   6-Dec-17 10:01
==>More News
*Data and information is provided for informational purposes only, and is not intended for trading purposes.*
*By accessing the Relationalstocks.com web site, a user agrees that RelationalStocks.com shall be not liable for any errors or delays in the content.*